H.C. Wainwright Reiterates Buy Rating on Protagonist Therapeutics (PTGX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| (NASDAQ: PTGX) | Delayed: 140.24 +0.87 (0.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $139.37 | 52 Week High | $24.52 | |||
| Open | $140.73 | 52 Week Low | $10.02 | |||
| Day High | $144.27 | P/E | N/A | |||
| Day Low | $139.91 | EPS | $0.00 | |||
| Volume | 674,717 | |||||
